FDA urges maker to recall Limbrel after liver and lung injury reports
The FDA asked Primus Pharmaceuticals to recall a product touted as easing osteoarthritis but linked to liver injury and a lung condition.
by Andrew Joseph
Dec 05, 2017
1 minute
The Food and Drug Administration has asked Primus Pharmaceuticals to recall a product touted to address “the metabolic processes associated with osteoarthritis” but that the agency says comes
You’re reading a preview, subscribe to read more.
Start your free 30 days